Myeloproliferative Disorders Research Consortium

Introduction. The Research Consortium for Myeloproliferative diseases (MPD-RC) is an international, multi-institutional, no-profit group, funded by the National Cancer Institute, whose mission is to coordinate, facilitate, and conduct basic and clinical research of genetic and cellular mechanisms of myeloproliferative neoplasms Philadelphia (Ph) chromosome negative. The ultimate goal is to develop new therapeutic strategies to improve the management of patients with this type of disease

Aims. The clinical research projects include studies with patients diagnosed with essential thrombocythemia, polycythemia vera and myelofibrosis. The studies are based on some of the results of previous projects, new therapies becoming available and strategies that need to be evaluated. The start of clinical trials that directly assess the biomarkers responsible for the progression of the disease will provide the opportunity for these patients to receive better care, and hopefully, better prognosis. The unique link between laboratory and clinical studies will speed up the timelines to test drugs and new therapies

Type of study. 13 multicenter, international phase I through III studies

Population. 331 patients enrolled in active studies diagnosed for Polycythemia Vera, Essential thrombocythemia, Myelofibrosis (Primary, Post-PV, Post-ET)

Centers. 
32 USA + 14 European centers (Italy, UK, France, Germany)

Promoter.
 MPD-RC

Status.
 8 ongoing studies